在患有严重COVID-19感染的血液恶性患者中使用托西利祖马布 - 病例系列报告
Chunlan Fu1, Yuanyuan Zhu2, Weijia Huang2
1Department of Hematology, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji, Zhejiang, 311800, People's Republic of China.
托西利祖马布在5名患有血液性恶性瘤的患者中有效治疗了严重的COVID-19. 这种干白素-6抑制剂改善了症状,并没有出现严重的不良反应,提供了一个有前途的治疗选择.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 传染性疾病 传染性疾病
背景情况:
- 患有血液性恶性瘤的患者经常经历严重的免疫缺陷,增加他们患重症COVID-19的风险.
- 托西利祖马布 (tocilizumab) 是一种干白素-6 (IL-6) 抑制剂,推用于严重的COVID-19,但其在免疫功能低下的癌症患者中的使用尚未得到充分证实.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Treatment Resistant Cancers
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
COPD: Management Using Bronchodilators and Corticosteroids
Immunodeficiency Diseases
There are three main causes of immunodeficiency...
